Peningkatan profil klinik-hematologi pada pasien sindrom mielodisplasia multilini paska splenektomi total
Keywords:myelodysplasia syndrome, splenomegali, splenektomi
Myelodysplasia syndrome (MDS) is a hematologic disorder manifested by cytopenia and rarely with splenomegaly. Clinical complaints that often accompany symptoms of anemia and when experiencing splenomegaly, the patient feels a full stomach or sometimes pain in the upper left abdomen. We report a case of a 55 year old woman with a full stomach complaint with a history of thrombocytopenia. From the peripheral blood examination, observation of thrombocytopenia was obtained with suspicion of the inflammatory process and physical examination of splenomegaly. Bone marrow aspiration studies revealed a multi-line cytopenic refractory MDS. Patients receive immunosuppressant therapy without blood transfusions. After 1 year of treatment the patient complained of fatigue and upper left abdominal pain. The results showed pancytopenia and splenomegaly. The doctor and patient discussion agreed to the splenectomy. The patient had no complications after splenectomy and for 11 months the patient felt complaint free and normal hematological parameters with a good quality of life. This case report suggests that splenectomy can be an alternative therapy for MDS that is refractory to previous therapy and is complaining of splenomegaly. Splenectomy can improve the clinical complaints and hematologic profile of MDS patients with splenomegaly.
Steensma DP. Myelodysplastic syndromes current treatment algorithm 2018. Blood Cancer Journal. 2018;8(47).
Nalluru SS., Jindal V, Piranavan P. et al. Splenic infarction secondary to myelodysplastic syndrome: unravelling more etiologies. AME Case Rep. 2019;3:31.
Kraus MD. Splenic histology and histopathology: an update. Semin Diagn Pathol. 2003;20(2):84-93.
Shimomura Y, Hara M, Katoh D, dkk. Enlarged spleen is associated with low neutrophil and platelet engraftment rates and poor survival after allogeneic stem cell transplantation in patients with acute myeloid leukemia and myelodysplastic syndrome. Ann Hematol. 2018;97(6):1049-1056.
Bourgeois E, Caulier MT, Rose C, dkk. Role of splenectomy in the treatment of myelodysplastic syndromes with peripheral thrombocytopenia: a report on six cases. Leukemia. 2001;15(6):950-953.
Bickenbach KA, Gonen M, Labow DM, dkk. Indications for and efficacy of splenectomy for haematological disorders. Br J Surg. 2013;100:794–800.
Rialon KL, Speicher PJ, Ceppa EP, dkk. Outcomes following splenectomy in patients with myeloid neoplasms. J Surg Oncol . 2015 Mar 15;111(4):389-95
Weledji P. Benefits and risks of splenectomy. Int J Surg . 2014;12(2):113-119
Kokhno AV, Mikhailova EA, Parovichnikova EN, dkk. Splenectomy in Patients with MDS. Blood. 2010;116(21):1879.
Uchida R, Nakano S, Namura K, dkk. Is splenectomy a contraindication for patients with myelodysplastic syndromes complicated by splenomegaly?. Ann Hematol. 2006;85(3):198-199.
How to Cite
Copyright (c) 2021 Jurnal Penyakit Dalam Udayana
This work is licensed under a Creative Commons Attribution 4.0 International License.
The copyright to this article is transferred to JPD (including without limitation, the right to publish the work in whole or in part in any and all forms of media, now or hereafter known) effective if and when the article is accepted for publication thus granting JPD all rights for the work so that both parties may be protected from the consequences of unauthorized use.
The copyright transfer covers the exclusive right to reproduce and distribute the article, including reprints, translations, photographic reproductions, microform, electronic form (offline,online) or any other reproductions of similar nature.
The authors warrant that their contribution is an original work not published elsewhere, that they have the full power to make this grant and that the article contains no matter unlawful or which invades the right to privacy or infringes any proprietary right.